Paion AG is a Germany-based biopharmaceutical company. The Company's main product is remimazolam, an intravenous ultra-short-acting benzodiazepine sedative and anesthetic. In the human body, remimazolam is metabolized to an inactive metabolite by tissue esterase and not metabolized by cytochrome-dependent hepatic pathways. In addition to that, remimazolam, which is in Phase III clinical development, can be reversed with flumazenil to terminate sedation and anesthesia, if necessary. The product can be used for general anesthesia in Europe and procedural sedation in the United States. The Company operates sites in Aachen, Germany, Cambridge, the United Kingdom, and New Jersey, the United States.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
04/08/26	€0.0500	-9.09%	11,329
03/08/26	€0.0550	0.00%	0
31/07/26	€0.0550	0.00%	50
30/07/26	€0.0550	0.00%	0
29/07/26	€0.0550	0.00%	0

End-of-day quote Deutsche Boerse AG

More quotes

Real-time Estimate Tradegate Other stock markets 14:25:08 05/08/2026 +03			5-day change	1st Jan Change
0.0600 ^EUR	+20.00%		-9.09%	+278.79%

Market Cap	144K 166K 134K 124K 233K 15.82M 236K 1.58M 620K 7.92M 625K 611K 26.22M	P/E 2021	-3.89x	P/E 2022	-53x
Enterprise Value	9.87M 11.39M 9.2M 8.46M 15.97M 1.08B 16.15M 108M 42.42M 542M 42.79M 41.84M 1.8B	EV / Sales 2021	14.1x	EV / Sales 2022	1.22x
Free-Float	100%	Yield 2021 *	-	Yield 2022	-

1 day	-9.09%
1 week	-9.09%
Current month	-9.09%
1 month	-7.41%
3 months	+13.64%
6 months	-64.16%
Current year	+278.79%

1 week	0.05	0.06
1 month	0.05	0.09
Current year	0.01	0.23
1 year	0	0.23
3 years	0	6.1
5 years	0	20.15
10 years	0	36.78

Manager	Title	Age	Since
Tilmann Bur CEO	Chief Executive Officer	62	01/09/2023
Sebastian Werner DFI	Director of Finance/CFO	-	01/06/2022

Paion AG Stock

Stocks

PA8K

DE000A3E5EG5

Biotechnology & Medical Research

Valuation: Paion AG

Chart: Paion AG

Latest news : Paion AG

Press Releases: Paion AG

News in other languages: Paion AG

Quotes and Performance

Course Extremes

Managers and Directors: Paion AG

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Director	Title	Age	Since
Karin Louise Dorrepaal BRD	Director/Board Member	65	01/10/2012
Hans Tanner BRD	Director/Board Member	75	01/06/2017
Markus Guilherme Dieken BRD	Director/Board Member	-	22/05/2019

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/27/22 A	Gregor Siebert	Buy	Director	1,121	0.0016%
1/12/21 A	James Phillips	Buy	Chief Executive Officer	8,500	0.0127%
6/8/20 A	James Phillips	Buy	Chief Executive Officer	13,158	0.0202%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PAION AG	+20.00%	-9.09%	+24,900.00%	-99.11%	411K
LONZA GROUP AG	+0.90%	-2.33%	+0.68%	+14.52%	48B
REVOLUTION MEDICINES, INC.	+2.04%	+8.64%	+412.01%	+563.16%	41.13B
IQVIA HOLDINGS INC.	+3.74%	-4.27%	+28.85%	+8.07%	37.56B
BEONE MEDICINES AG	+2.22%	+0.85%	+7.40%	+75.97%	35.91B
CELLTRION, INC.	+2.42%	+7.27%	+14.90%	+44.79%	29.86B
ASCENDIS PHARMA A/S	+0.35%	-2.66%	-	-	16.12B
MEDPACE HOLDINGS, INC.	+1.10%	-0.43%	+33.49%	+123.68%	16.05B
EUROFINS SCIENTIFIC SE	+1.25%	+1.52%	+4.62%	+18.66%	13.76B
ICON PUBLIC LIMITED COMPANY	+4.65%	-7.92%	-1.15%	-34.78%	12.1B
Average	+0.90%	-2.84%	+2,822.31%	+79.44%	25.05B
Weighted average by Cap.	+1.96%	-1.29%	+82.65%	+128.21%

	2021	2022
Net sales	7.13M 8.23M 6.64M 6.11M 11.54M 783M 11.67M 78.09M 30.65M 392M 30.91M 30.23M 1.3B	33.25M 38.39M 30.99M 28.51M 53.81M 3.65B 54.42M 364M 143M 1.83B 144M 141M 6.05B
Net income	-21.79M -25.15M -20.31M -18.68M -35.26M -2.39B -35.66M -239M -93.66M -1.2B -94.47M -92.39M -3.96B	-579K -669K -540K -496K -937K -63.57M -948K -6.34M -2.49M -31.81M -2.51M -2.46M -105M
Net Debt	13.77M 15.9M 12.84M 11.81M 22.29M 1.51B 22.54M 151M 59.2M 756M 59.71M 58.39M 2.51B	9.72M 11.23M 9.06M 8.34M 15.74M 1.07B 15.91M 107M 41.8M 534M 42.16M 41.23M 1.77B